Natasha Giordano has moved from Clear Point Learning to join PLx Pharma as its new president and chief executive officer.
Giordano has also been appointed to the US specialty pharma company’s board of directors, of which her predecessor Ronald Zimmerman will remain a member.
Zimmerman served as president and CEO from January 2004 until December 2015 and continues in his role as a founding investor and senior advisor, providing support for pre-commercialisation activities, regulatory affairs and business development.
Michael Valentino, executive chairman of the board, said: “We are excited to welcome Natasha to the PLx team as she is a strong leader with a broad range of sales, marketing and management experience, which will be an invaluable asset for PLx Pharma’s success and future growth prospects.
“We are confident Natasha will be a driving force for PLx as we transition from the development phase to the commercial launch of our lead product, PL2200 Aspirin.”
Giordano has over 25 years of leadership experience in the pharmaceutical and healthcare industries.
Prior to her time at Clear Point Learning, where she was its president and CEO, she served as president and CEO of both Healthcare Corporation of America and Xanodyne Pharmaceuticals.
Giordano said: “I am excited to be joining PLx Pharma at this critical pre-launch inflection point.”
“I look forward to building on the compelling clinical data and initial market access work the PLx management team has begun and to successfully launching PL2200 Aspirin into the U.S. market in 2017.”